by pbn | Jun 23, 2021 | Board of Directors
Alex Leech was the founding CEO of Alchemab Therapeutics and raised a £60m ($82m) Series A in 2021. He is a serial biotech CEO having led Creabilis, a leading European dermatology company, until its acquisition by Sienna Biopharmaceuticals Inc. in December 2016 and...
by pbn | Jun 23, 2021 | Board of Directors
John Kemp is currently the CSO of Syndesi Therapeutics. Former roles include Head of Neuroscience Discovery at Janssen, Belgium, and CEO of Evotec Neurosciences, which was spun-out from Evotec and raised a €25m Series A in 2004. Before joining Evotec, John was SVP and...
by pbn | Jun 23, 2021 | Board of Directors
Preben is 2N Pharma’s co-founder and CEO and brings broad business and finance experience from an international career spanning nine countries over 25 years. He is co-founder of clinical-stage vaccine company 2A Pharma, and chairman...
by pbn | Jun 6, 2021 | Board of Directors
John is 2N Pharma’s co-founder and CSO and brings broad management experience and in-depth research background. He was previously director of research at Medigene AG and is co-founder of the clinical-stage vaccine company 2A Pharma and two other biotech...
by pbn | Jun 23, 2021 | Board of Directors
Giles Dudley is a Portfolio Manager at the BioInnovation Institute in Copenhagen and non-voting board observer. He has more than 10 years experience with fundraising, business development, market due diligence and IP development in biotech startups. Giles has a PhD in...
Recent Comments